Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Bispecific | 1 | 2025 | 9 | 0.930 |
Why?
|
| Herpesviridae Infections | 1 | 2025 | 17 | 0.920 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 17 | 0.920 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 82 | 0.860 |
Why?
|
| Pseudomonas Infections | 1 | 2022 | 25 | 0.760 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 22 | 0.740 |
Why?
|
| Pneumonia | 1 | 2022 | 89 | 0.720 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 38 | 0.690 |
Why?
|
| Anti-Bacterial Agents | 5 | 2025 | 523 | 0.490 |
Why?
|
| Antiviral Agents | 2 | 2025 | 112 | 0.390 |
Why?
|
| Humans | 11 | 2025 | 28168 | 0.260 |
Why?
|
| Organ Transplantation | 1 | 2025 | 14 | 0.240 |
Why?
|
| Communicable Diseases | 1 | 2025 | 21 | 0.230 |
Why?
|
| Herpesviridae | 1 | 2025 | 3 | 0.230 |
Why?
|
| Macrolides | 1 | 2025 | 19 | 0.230 |
Why?
|
| Drug Hypersensitivity | 1 | 2025 | 23 | 0.230 |
Why?
|
| Transplant Recipients | 2 | 2021 | 12 | 0.230 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 19 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 1 | 2025 | 36 | 0.220 |
Why?
|
| Coccidioidomycosis | 1 | 2024 | 13 | 0.220 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 283 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 51 | 0.200 |
Why?
|
| Peritoneal Dialysis | 1 | 2021 | 4 | 0.190 |
Why?
|
| Peritonitis | 1 | 2021 | 15 | 0.190 |
Why?
|
| Acetates | 1 | 2021 | 45 | 0.180 |
Why?
|
| Quinazolines | 1 | 2021 | 32 | 0.180 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 1 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 71 | 0.180 |
Why?
|
| Cryptococcosis | 1 | 2021 | 32 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 109 | 0.170 |
Why?
|
| Risk Factors | 1 | 2025 | 2087 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2024 | 2558 | 0.150 |
Why?
|
| Pneumonia, Bacterial | 1 | 2018 | 18 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 31 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 29 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 50 | 0.150 |
Why?
|
| Aged | 3 | 2024 | 5417 | 0.130 |
Why?
|
| Male | 5 | 2025 | 13511 | 0.130 |
Why?
|
| Bacteria | 1 | 2018 | 282 | 0.120 |
Why?
|
| Incidence | 2 | 2025 | 562 | 0.080 |
Why?
|
| Middle Aged | 3 | 2025 | 7164 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2025 | 61 | 0.060 |
Why?
|
| Clarithromycin | 1 | 2025 | 7 | 0.060 |
Why?
|
| Anaphylaxis | 1 | 2025 | 7 | 0.060 |
Why?
|
| Erythromycin | 1 | 2025 | 15 | 0.060 |
Why?
|
| Azithromycin | 1 | 2025 | 11 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2025 | 72 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 54 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2025 | 77 | 0.060 |
Why?
|
| Social Media | 1 | 2025 | 56 | 0.060 |
Why?
|
| Coccidioides | 1 | 2024 | 14 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 28 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 17 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2025 | 255 | 0.050 |
Why?
|
| Comorbidity | 1 | 2024 | 257 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 67 | 0.050 |
Why?
|
| Adult | 2 | 2025 | 7765 | 0.050 |
Why?
|
| Female | 3 | 2025 | 15192 | 0.050 |
Why?
|
| Gentamicins | 1 | 2021 | 15 | 0.050 |
Why?
|
| Oklahoma | 1 | 2024 | 1005 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 1149 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 5 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2018 | 28 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 69 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 1257 | 0.040 |
Why?
|
| Child | 1 | 2024 | 2253 | 0.030 |
Why?
|
| Young Adult | 1 | 2024 | 2738 | 0.030 |
Why?
|
| Adolescent | 1 | 2024 | 3128 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 611 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2021 | 0.030 |
Why?
|